The 2024 Finished Product Report offers a comprehensive overview of six key markets: dietary supplements, pharmaceuticals, food and beverage, pet nutrition, infant formula and clinical nutrition/medical foods. Together, these categories reached US$52.4 billion in sales in 2023, primarily influenced by inflation and higher prices.
Some key takeaways from the report:
- The pet nutrition segment exhibited strong growth of 8.8% annually, reaching US$1.5 billion in sales in 2023.
- The supplement category also grew, but the dollar increase was driven primarily by increased prices as a result of fish oil shortages.
- The DHA-fortified infant nutrition market is by far the largest of the consumer product categories, although birth rates across the globe are on the decline, resulting in a growth of 2.9% in 2023.
- Looking ahead, sales of EPA and DHA finished products are poised to increase an average of 3.3% annually through 2025.
The report encompasses market statistics and trend analyses across 11 regions for 2022 and 2023, with forecasts extending through 2025. Click here to request a sample of the report.
The second report, EPA and DHA Supplementation and Attention Deficit Hyperactivity Disorder, explores the latest research on the impact of EPA+DHA omega-3 supplementation on ADHD and associated ADHD outcomes. The report was created using GOED’s Clinical Study Database (CSD), a powerful tool that catalogs all human clinical studies on EPA and DHA omega-3s.
EPA+DHA have been suggested to play a potential role in reducing the symptoms associated with ADHD and the report analyzes the studies conducted on people who have been diagnosed with ADHD, or people who have been assessed using ADHD criteria for symptoms. The report also provides key takeaways and suggests next steps for research.
The ADHD report is available for purchase on the GOED website for US$199. GOED members have free access to the report.
